Nama's AI scorecard currently rates RadNet Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is RDNT's P/E ratio?

RadNet trades at a trailing price-to-earnings ratio of 172.7.

When does RDNT report earnings?

RadNet's next scheduled report is on Nov 8, 2026. Analysts expect EPS of $0.22.

What is the RDNT price target?

The median analyst price target from 8 analysts is $95.50, with a range of $79.00 – $105.00.

Is RDNT Shariah compliant?

Nama's AAOIFI-style screen reads RadNet as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

RadNet (RDNT)

Healthcare · Diagnostics Research · NASDAQ

RadNet (RDNT) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $5.98B, a trailing price-to-earnings ratio of 172.7 and a free-cash-flow yield of 1.5%. Over the most recent reported fiscal year, revenue grew 11.5% and free cash flow per share grew 89.3%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -13.1% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-18.9%

How far the last close sits under the highest price of the past five years.

Market cap	$5.98B
Trailing P/E	172.7
Price / book	5.5
Price / sales	2.6
FCF yield	1.5%
Dividend yield	—
Gross margin	11.5%
Operating margin	4.0%
Net margin	-0.9%
Revenue growth (YoY)	+11.5%
Revenue growth (3-yr annual)	+12.6%
EPS growth (YoY)	-38.1%
FCF/share growth (YoY)	+89.3%
Beta	1.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

RDNT earnings

Next report: Nov 8, 2026 (Q3 2026, EPS estimate $0.22). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 9, 2026	$0.29	$0.20	+45.0%	$622.72M
Q1 2026	May 10, 2026	-$0.28	-$0.19	-47.4%	$575.63M
Q4 2025	Mar 2, 2026	$0.23	$0.20	+15.0%	$547.71M
Q3 2025	Nov 9, 2025	$0.20	$0.23	-13.0%	$522.87M

RDNT analyst price target

Median target $95.50 from 8 analysts, ranging $79.00 – $105.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live RDNT data on Nama Insights →

RDNT FAQ

Is RDNT a buy?: Nama's AI scorecard currently rates RadNet Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is RDNT's P/E ratio?: RadNet trades at a trailing price-to-earnings ratio of 172.7.
When does RDNT report earnings?: RadNet's next scheduled report is on Nov 8, 2026. Analysts expect EPS of $0.22.
What is the RDNT price target?: The median analyst price target from 8 analysts is $95.50, with a range of $79.00 – $105.00.
Is RDNT Shariah compliant?: Nama's AAOIFI-style screen reads RadNet as Not Shariah Compliant. At least one of the three ratios or the industry test failed.